New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareVesugen vs MOTS-c

Vesugen vs MOTS-c

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Vesugen
Anti-Aging & Longevity
MOTS-c
Summary
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
Half-Life
Short (minutes); sustained gene-regulatory effects
Estimated 1–2 hours
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
5–15 mg
Frequency
Daily for 10–30 days
3–5 times per week
Key Benefits
  • Supports vascular endothelial cell function and integrity
  • May reduce endothelial inflammation and dysfunction
  • Anti-aging effects on blood vessel walls
  • Potential benefits in early atherosclerosis and vascular aging
  • Supports nitric oxide-mediated vascular tone
  • Reduces endothelial apoptosis from oxidative stress
  • Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
  • Improves insulin sensitivity and glucose metabolism
  • Enhances exercise capacity and endurance
  • Reduces age-related metabolic decline
  • Activates AMPK — the master metabolic regulator
  • Promotes fat oxidation
  • Anti-inflammatory effects
  • May extend healthspan via mitochondrial optimization
  • Increases energy and reduces fatigue
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant vascular adverse events reported at standard doses
  • Injection site irritation
  • Fatigue during initial adaptation
  • Unknown long-term profile (limited human data)
Stacks With